Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA
NCT07413146Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
Randomised, open-label trial of capecitabine and oxaliplatin in colon cancer (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: 2-year Disease-Free Survival. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
capecitabineoxaliplatin
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT07413146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07413146.